Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug
French drug maker Sanofi said Wednesday that it will acquire Kadmon Pharmaceuticals for $1.9 billion, bolstering its transplant medicines business with a newly approved treatment for graft-versus-host disease.
The all-cash transaction sees Kadmon shares worth $9.50 per share, or a 79% premium to Tuesday’s closing price.
Read Original Article: Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug »
